CoChat

Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 14 of the 24 sources its claims cite were checked for support.

Abstract

Aim: To evaluate the activity and safety of the PD-1 antibody pembrolizumab in adult patients with advanced osteosarcoma. Material and methods: The study was a single-arm, open-label, phase 2 trial in patients with unresectable, relapsed osteosarcoma. The primary endpoint was clinical benefit rate (CBR) at 18 weeks of treatment, defined as complete response, partial response, or stable disease using RECIST v1.1. The trial had a Simon´s two-stage design, and ≥ 3 of 12 patients with clinical benefit in stage 1 were required to proceed to stage 2. The trial is registered with ClinicalTrials.gov, number NCT03013127. NanoString analysis was performed to explore tumor gene expression signatures and pathways. Results: Twelve patients were enrolled and received study treatment. No patients had clinical benefit at 18 weeks of treatment, and patient enrollment was stopped after completion of stage 1. Estimated median progression-free survival was 1.7 months (95% CI 1.2–2.2). At time of data cut-off, 11 patients were deceased due to osteosarcoma. Median overall survival was 6.6 months (95% CI 3.8–9.3). No treatment-related deaths or drug-related grade 3 or 4 adverse events were observed. PD-L1 expression was positive in one of 11 evaluable tumor samples, and the positive sample was from a patient with a mixed treatment response. Conclusion: In this phase 2 study in advanced osteosarcoma, pembrolizumab was well-tolerated but did not show clinically significant antitumor activity. Future trials with immunomodulatory agents in osteosarcoma should explore combination strategies in patients selected based on molecular profiles associated with response.

Overview

CoChat Summary

TL;DR

In this single-arm phase 2 trial, pembrolizumab was well tolerated but showed no clinically significant antitumor activity in adults with advanced osteosarcoma. Enrollment stopped after stage 1 because none of 12 patients achieved clinical benefit at 18 weeks.

Key findings

  • No patients had clinical benefit (CR, PR, or SD) at 18 weeks; 0 of 12 reached the primary endpoint, so the Simon two-stage trial did not proceed to stage 2.
  • Estimated median progression-free survival was 1.7 months (95% CI 1.2–2.2), and median overall survival was 6.6 months (95% CI 3.8–9.3); 11 patients were deceased due to osteosarcoma at data cut-off.
  • Adverse events of grade 3 or higher occurred in 7 of 12 patients (58%), but no treatment-related deaths or drug-related grade 3 or 4 adverse reactions were observed.
  • PD-L1 expression was positive in 1 of 11 evaluable tumor samples; that patient had a mixed radiological and metabolic response, with reduction in lung and kidney metastases but progression of abdominal and pelvic metastases.

Methods

  • Single-arm, open-label, phase 2 trial (PROMO; NCT03013127) in patients aged ≥18 years with unresectable, relapsed osteosarcoma; 12 patients were enrolled across two sites between May 31, 2017, and Sept 27, 2018.
  • Pembrolizumab 200 mg was given intravenously every 21 days; primary endpoint was clinical benefit rate at 18 weeks by RECIST v1.1, with secondary endpoints including PFS, OS, ORR, PET/CT response, quality of life, safety, and tolerability.
  • Exploratory analyses included PD-L1 immunohistochemistry (clone 22C3) and NanoString PanCancer IO 360 gene expression profiling on available fresh frozen tissue.

Limitations

  • The paper states that due to rapid disease progression, only four patients completed EORTC QLQ-C30 questionnaires during treatment, so quality of life results are not reported.
  • The trial stopped after stage 1 with only 12 patients, limiting statistical precision and preventing evaluation of the planned stage 2 population.
  • Evident from the text: this was a single-arm study without a control group, and the molecular analyses were exploratory and based on small available sample numbers (11 PD-L1 samples, 6 fresh frozen samples), so no definitive predictive conclusions can be drawn.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00262-021-02876-w

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Waterfall plot showing best RECIST response. Individual patients are represented by vertical bars and the change in tumor size according to RECIST v1.1 is depicted on the Y-axis. Two patients did not undergo radiological evaluation and are not included
Fig. 1 Waterfall plot showing best RECIST response. Individual patients are represented by vertical bars and the change in tumor size according to RECIST v1.1 is depicted on the Y-axis. Two patients did not undergo radiological evaluation and are not includedCC BY · PubMed Central
Fig. 2 Photomicrographs of immunohistochemical staining with monoclonal anti-PD-L1 antibody (clone 22C3; Dako). a > 50% positive membranous staining of tumor cells. Scale bar 50 μm. b Negative staining. Scale bar 100 μm
Fig. 2 Photomicrographs of immunohistochemical staining with monoclonal anti-PD-L1 antibody (clone 22C3; Dako). a > 50% positive membranous staining of tumor cells. Scale bar 50 μm. b Negative staining. Scale bar 100 μmCC BY · PubMed Central
Fig. 3 Baseline images and response evaluation after treatment with pembrolizumab in study patient 12 (PROMO-12). a CT images and b 18F-FDG PET/CT images at baseline (left panel) and after two cycles of pembrolizumab (right panel). Arrows indicate reduced uptake of 18F-FDG and tumor size in lung and kidney metastases, and arrowheads indicate progressive abdominal and pelvic metastases
Fig. 3 Baseline images and response evaluation after treatment with pembrolizumab in study patient 12 (PROMO-12). a CT images and b 18F-FDG PET/CT images at baseline (left panel) and after two cycles of pembrolizumab (right panel). Arrows indicate reduced uptake of 18F-FDG and tumor size in lung and kidney metastases, and arrowheads indicate progressive abdominal and pelvic metastasesCC BY · PubMed Central
Fig. 4 Gene expression analysis of tumor samples using the NanoString platform. a Abundance of various cell type populations across different samples. The cell type score is calculated based on cell-type specific gene expression markers. b Pathways showing differential behavior in PROMO-12 compared to the remaining samples. Pathway scores are calculated based on gene expression data using nSolver V4 software and oriented such that increasing score corresponds to increased expression. c Normalized gene expression values of top 28 differential expressed genes involved in these pathways. For both plots, rows are centered and unit variance scaling is applied to rows. Both rows and columns are clustered using correlation distance and average linkage. In b and c, samples were analyzed in duplicate and both duplicates are shown
Fig. 4 Gene expression analysis of tumor samples using the NanoString platform. a Abundance of various cell type populations across different samples. The cell type score is calculated based on cell-type specific gene expression markers. b Pathways showing differential behavior in PROMO-12 compared to the remaining samples. Pathway scores are calculated based on gene expression data using nSolver V4 software and oriented such that increasing score corresponds to increased expression. c Normalized gene expression values of top 28 differential expressed genes involved in these pathways. For both plots, rows are centered and unit variance scaling is applied to rows. Both rows and columns are clustered using correlation distance and average linkage. In b and c, samples were analyzed in duplicate and both duplicates are shownCC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 0 Not valid · 2 Not checked · 23 Own results and interpretations

18 more claims · 1 with their cited sources checked

Create a free account to see all 36 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 9
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

Metadata

Authors
Boye, K., Longhi, A., Guren, T., Lorenz, S., Næss, S., Pierini, M., Taksdal, I., Lobmaier, I., Cesari, M., Paioli, A., Løndalen, A. M., Setola, E., Hompland, I., Meza-Zepeda, L. A., Sundby Hall, K., & Palmerini, E.
Affiliations
  • Oslo University Hospital (NO)
  • Istituto Ortopedico Rizzoli (IT)
Corresponding author
Boye, Kjetil
Venue
Cancer Immunology, Immunotherapy
Published
2021-02-12
Volume
70
Issue
9
Pages
2617-2624
ISSN
  • 0340-7004 (ISSN-L)
  • 1432-0851
OpenAlex
W3128411524
Cited by
112
References
27
Citations by year
2026: 19 · 2025: 27 · 2024: 16 · 2023: 22 · 2022: 21 · 2021: 6
FWCI
10.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancer Immunology Immunotherapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
Funders
  • The Radium Hospital Foundation
  • Oslo University Hospital Trust
  • Merck Sharp and Dohme
  • University of Oslo
Topics
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone Tumor Diagnosis and Treatments
Keywords
pembrolizumab, PD-1 inhibitors, PD-L1 expression, relapsed osteosarcoma, anticancer activity, treatment safety, immunotherapy
MeSH terms
Positron Emission Tomography Computed Tomography, Immune Checkpoint Inhibitors, Bone Neoplasms, Combined Modality Therapy, Humans, Neoplasm Metastasis, Neoplasm Staging, Osteosarcoma, Biomarkers, Tumor, Treatment Outcome, Fluorodeoxyglucose F18, Gene Expression Profiling, B7-H1 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.